Genmab — Oktober 2017
-
SEB sænker målkurs på Genmab til 1280 fra 1430. SEB h
ar stadig en hold anbefaling. -
EL - SEB lowered their sales estimat for Darzalex
-
meanwhile this small study (36 patie
nts for AML or MDS) now recruiting - https://clinicaltrials.gov/ct2/show/NCT03067571 -
enig JKY.
-
Da jeg er ung og ikke har så mange forpligtelser, er jeg ikke afhængig af de penge, jeg har investeret, hvorfor jeg har en høj risikovillighed (ikke så høj, at vi snakker penny-stocks). Derfor er jeg begyndt at tænke, om Genmab overhovedet hører inde i den kategori? Er Genmab blevet en så stor virksomhed, at risikoen er blevet lille og dermed også mulighederne for afkast? Det virker som om den eneste virkelige kurstrigger er, hvis Darzalex virker i solide,
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind